Patents by Inventor Frederic Revah

Frederic Revah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9284252
    Abstract: The present invention relates to methods of treating benign hyperproliferative diseases of the epidermis by administering a composition comprising at least one jasmonate ester derivative. In particular, the present invention provides jasmonate ester derivatives as potent compounds useful for the treatment of disorders such as actinic keratoses with reduced side effects.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: March 15, 2016
    Assignee: SEPAL PHARMA LTD.
    Inventors: Max Herzberg, Frederic Revah
  • Publication number: 20150080430
    Abstract: The present invention relates to methods of treating benign hyperproliferative diseases of the epidermis by administering a composition comprising at least one jasmonate ester derivative. In particular, the present invention provides jasmonate ester derivatives as potent compounds useful for the treatment of disorders such as actinic keratoses with reduced side effects.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 19, 2015
    Applicant: SEPAL PHARMA LTD.
    Inventors: Max HERZBERG, Frederic REVAH
  • Patent number: 8431119
    Abstract: The present invention relates to pharmaceutical compositions that act on the p53 protein or its gene and methods of use for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: April 30, 2013
    Assignee: Aventis Pharma S.A.
    Inventors: Jacques Mallet, Frederic Revah, Jean-Marie Stutzmann
  • Publication number: 20120083529
    Abstract: The present invention relates to methods of treating benign hyperproliferative diseases of the epidermis by administering a composition comprising at least one jasmonate ester derivative, preferably methyl jasmonate. In particular, the present invention provides jasmonate ester derivatives as potent compounds useful for the treatment of disorders such as actinic keratoses with reduced side effects.
    Type: Application
    Filed: June 3, 2010
    Publication date: April 5, 2012
    Applicant: SEPAL PHARMA LTD
    Inventors: Max Herzberg, Frederic Revah
  • Publication number: 20090170199
    Abstract: The present invention relates to a method for the separation of biological objects in a solution which have different viscoelastic properties, wherein said method comprises a filtration step allowing the higher viscoelastic biological objects to pass through the membrane while retaining the lower viscoelastic biological objects above the membrane, and a recovery step wherein the separated lower viscoelastic biological objects are recovered above or onto the membrane and/or the separated higher viscoelastic biological objects are recovered in the filtrate. Advantageously, the biological objects are cells. More advantageously, the recovered cells are viable cells. In one preferred embodiment, the cells are tumor cells. In another preferred embodiment, the cells are fetal cells and the method finds an application in prenatal diagnosis.
    Type: Application
    Filed: June 19, 2008
    Publication date: July 2, 2009
    Inventors: Ryan Stephen RAZ, Anthony PRESTA, Laurent SAFAR, Frederic REVAH
  • Publication number: 20080032284
    Abstract: The present invention relates to pharmaceutical compositions that act on the p53 protein or its gene and methods of use for the treatment of neurodegenerative diseases.
    Type: Application
    Filed: August 22, 2007
    Publication date: February 7, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Jacques MALLET, Frederic REVAH, Jean-Marie STUTZMANN
  • Publication number: 20050244381
    Abstract: A defective recombinant adenovirus including at least one DNA sequence coding for all or an active part of a superoxide dismutase or a derivative thereof. The therapeutical use thereof and corresponding pharmaceutical compositions are also disclosed.
    Type: Application
    Filed: June 16, 2005
    Publication date: November 3, 2005
    Inventors: Jacques Mallet, Frederic Revah, Michel Perricaudet, Martine Barkats
  • Publication number: 20050069523
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic factor (GDNF), preparation thereof, and use thereof for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: July 9, 2003
    Publication date: March 31, 2005
    Inventors: Philippe Horellou, Jacques Mallet, Michel Perricaudet, Frederic Revah, Emmanuelle Vigne
  • Publication number: 20050065218
    Abstract: The present invention relates to the utilization of Alverine or its metabolites, alone or in combination with a tricyclic antidepressant or a specific serotonin reuptake inhibitor, for the preparation of pharmaceutical compositions for the treatment of depression.
    Type: Application
    Filed: June 14, 2004
    Publication date: March 24, 2005
    Inventors: Jacques Migeon, Frederic Revah
  • Publication number: 20040175363
    Abstract: The present invention relates to a defective adenovirus comprising at least a DNA sequence coding for all or an active part of glutathione peroxidase or a derivative thereof. It also relates to their utilisation in therapy and to the corresponding pharmaceutical compositions.
    Type: Application
    Filed: February 2, 2004
    Publication date: September 9, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Martine Barkats, Jacques Mallet, Frederic Revah
  • Publication number: 20030059455
    Abstract: A defective recombinant adenovirus including at least one DNA sequence coding for all or an active part of a superoxide dismutase or a derivative thereof. The therapeutical use thereof and corresponding pharmaceutical compositions are also disclosed.
    Type: Application
    Filed: January 13, 1997
    Publication date: March 27, 2003
    Applicant: RHONE-POULENC RORER S.A.
    Inventors: MARTINE BARKATS, JACQUES MALLET, MICHEL PERRICAUDET, FREDERIC REVAH
  • Publication number: 20020164303
    Abstract: The present invention relates to methods and compositions for delivering nucleic acids to motor neurons by administering the nucleic acids to muscle tissue. The invention relates to methods for treating pathologies of the nervous system, such as trauma and neurodegenerative diseases.
    Type: Application
    Filed: July 16, 1999
    Publication date: November 7, 2002
    Inventors: FRANCOISE FINIELS, MINERVA GIMENEZ-RIBOTTA, JACQUES MALLET, ALAIN PRIVAT, FREDERIC REVAH
  • Publication number: 20020071828
    Abstract: A method used to stimulate neural regeneration can be applied to peripheral nerves as well as nerves of the central nervous system, especially of the spinal cord. The invention notably employs a system including a biocompatible cuff, into which a system of expression of a neurotrophic factor is inserted.
    Type: Application
    Filed: September 23, 1999
    Publication date: June 13, 2002
    Inventors: PASCAL PEULVE, FREDERIC REVAH, MARC TADIE
  • Publication number: 20020031493
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic factor (GDNF), preparation thereof, and use thereof for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: August 1, 1997
    Publication date: March 14, 2002
    Applicant: RHONE-POULENC RORER S.A.
    Inventors: PHILIPPE HORELLOU, JACQUES MALLET, MICHEL PERRICAUDET, FREDERIC REVAH, EMMANUELLE VIGNE
  • Publication number: 20010029249
    Abstract: The present invention relates to a defective adenovirus comprising at least a DNA sequence coding for all or an active part of glutathione peroxidase or a derivative thereof. It also relates to their utilisation in therapy and to the corresponding pharmaceutical compositions.
    Type: Application
    Filed: May 1, 1997
    Publication date: October 11, 2001
    Inventors: MARTINE BARKATS, JACQUES MALLET, FREDERIC REVAH
  • Patent number: 6140112
    Abstract: The present invention pertains to the use of compounds affecting the activity of transcription factors for the preparation of a pharmaceutical composition for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: April 25, 1996
    Date of Patent: October 31, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Jacques Mallet, Frederic Revah, Jean-Jacques Robert